Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 152

1.

Interferon Signaling Is Diminished with Age and Is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer.

Sceneay J, Goreczny GJ, Wilson K, Morrow S, DeCristo MJ, Ubellacker JM, Qin Y, Laszewski T, Stover DG, Barrera V, Hutchinson JN, Freedman RA, Mittendorf EA, McAllister SS.

Cancer Discov. 2019 Jun 19. doi: 10.1158/2159-8290.CD-18-1454. [Epub ahead of print]

PMID:
31217296
2.

Arti Hurria, M.D.: A tribute to her shining legacy in the Alliance for Clinical Trials in Oncology.

Alliance Cancer in the Older Adult Committee, Adjei A, Buckner JC, Cathcart-Rake E, Chen H, Cohen HJ, Dao D, De Luca JE, Feliciano J, Freedman RA, Goldberg RM, Hopkins J, Hubbard J, Jatoi A, Karuturi M, Kemeny M, Kimmick GG, Klepin HD, Krok-Schoen JL, Lafky JM, Le-Rademacher JG, Li D, Lichtman SM, Maggiore R, Mandelblatt J, Morrison VA, Muss HB, Ojelabi MO, Sedrak MS, Subbiah N, Sun V, Tuttle S, VanderWalde N, Wildes T, Wong ML, Woyach J.

J Geriatr Oncol. 2019 Jun 11. pii: S1879-4068(19)30158-4. doi: 10.1016/j.jgo.2019.05.011. [Epub ahead of print] Review. No abstract available.

PMID:
31201095
3.

Developing a patient decision aid for women aged 70 and older with early stage, estrogen receptor positive, HER2 negative, breast cancer.

Schonberg MA, Freedman RA, Recht AR, Jacobson AR, Aliberti GM, Karamourtopoulos M, Nakhlis F, McCarthy EP, Pories SE, Sharma R, Dominici LS.

J Geriatr Oncol. 2019 May 23. pii: S1879-4068(19)30039-6. doi: 10.1016/j.jgo.2019.05.004. [Epub ahead of print]

PMID:
31130442
4.

Treatment Patterns Among De Novo Metastatic Cancer Patients Who Died Within 1 Month of Diagnosis.

Sineshaw HM, Jemal A, Ng K, Osarogiagbon RU, Robin Yabroff K, Ruddy KJ, Freedman RA.

JNCI Cancer Spectr. 2019 Jun;3(2):pkz021. doi: 10.1093/jncics/pkz021. Epub 2019 Apr 15.

5.

Impact of a Pre-Operative Exercise Intervention on Breast Cancer Proliferation and Gene Expression: Results from the Pre-Operative Health and Body (PreHAB) Study.

Ligibel JA, Dillon D, Giobbie-Hurder A, McTiernan A, Frank E, Cornwell M, Pun M, Campbell N, Dowling RJO, Chang MC, Tolaney S, Chagpar AB, Yung RL, Freedman RA, Dominici LS, Golshan M, Rhei E, Taneja K, Huang Y, Brown M, Winer EP, Jeselsohn R, Irwin ML.

Clin Cancer Res. 2019 Apr 24. doi: 10.1158/1078-0432.CCR-18-3143. [Epub ahead of print]

PMID:
31018921
6.

Who Are the Patients in Our Clinical Trials for Cancer?

Freedman RA, Ruddy KJ.

J Clin Oncol. 2019 Jun 20;37(18):1519-1523. doi: 10.1200/JCO.19.00382. Epub 2019 Apr 17. No abstract available.

PMID:
30995173
7.

Older-Patient-Specific Cancer Trials: A Pooled Analysis of 2,277 Patients (A151715).

Dao D, Zemla T, Jatoi A, Freedman RA, Hurria A, Muss H, Cohen HJ, Shulman LN, Citron M, Budman D, McMurray R, Partridge A, Carey L, Sedrak MS, Lafky JM, Le-Rademacher JG.

Oncologist. 2019 Jun;24(6):e284-e291. doi: 10.1634/theoncologist.2018-0803. Epub 2019 Apr 11.

PMID:
30975921
8.

TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.

Freedman RA, Gelman RS, Anders CK, Melisko ME, Parsons HA, Cropp AM, Silvestri K, Cotter CM, Componeschi KP, Marte JM, Connolly RM, Moy B, Van Poznak CH, Blackwell KL, Puhalla SL, Jankowitz RC, Smith KL, Ibrahim N, Moynihan TJ, O'Sullivan CC, Nangia J, Niravath P, Tung N, Pohlmann PR, Burns R, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU; Translational Breast Cancer Research Consortium.

J Clin Oncol. 2019 May 1;37(13):1081-1089. doi: 10.1200/JCO.18.01511. Epub 2019 Mar 12.

PMID:
30860945
9.

Impact of Subtype on Survival of Young Patients With Stage IV Breast Cancer.

Ogiya R, Sagara Y, Niikura N, Freedman RA.

Clin Breast Cancer. 2019 Jun;19(3):200-207.e1. doi: 10.1016/j.clbc.2019.01.005. Epub 2019 Jan 29.

PMID:
30795886
10.

Examining Associations of Racial Residential Segregation With Patient Knowledge of Breast Cancer and Treatment Receipt.

Bonner SN, Clark C, Keating NL, Kouri EM, Freedman RA.

Clin Breast Cancer. 2019 Jun;19(3):178-187.e3. doi: 10.1016/j.clbc.2018.12.001. Epub 2018 Dec 8.

PMID:
30685264
11.

Clinical Impact of Second Opinion Radiology Consultation for Patients With Breast Cancer.

Whorms DS, Giess CS, Golshan M, Freedman RA, Bunnell CA, Alper EC, Losk K, Khorasani R.

J Am Coll Radiol. 2019 Jun;16(6):814-823. doi: 10.1016/j.jacr.2018.10.010. Epub 2018 Dec 20.

PMID:
30579707
12.

Age and the Risk of Paclitaxel-Induced Neuropathy in Women with Early-Stage Breast Cancer (Alliance A151411): Results from 1,881 Patients from Cancer and Leukemia Group B (CALGB) 40101.

Barginear M, Dueck AC, Allred JB, Bunnell C, Cohen HJ, Freedman RA, Hurria A, Kimmick G, Le-Rademacher JG, Lichtman S, Muss HB, Shulman LN, Copur MS, Biggs D, Ramaswamy B, Lafky JM, Jatoi A.

Oncologist. 2019 May;24(5):617-623. doi: 10.1634/theoncologist.2018-0298. Epub 2018 Nov 8.

PMID:
30409792
13.

Haemophagocytic lymphohistiocytosis complicating pembrolizumab treatment for metastatic breast cancer in a patient with the PRF1A91V gene polymorphism.

Al-Samkari H, Snyder GD, Nikiforow S, Tolaney SM, Freedman RA, Losman JA.

J Med Genet. 2019 Jan;56(1):39-42. doi: 10.1136/jmedgenet-2018-105485. Epub 2018 Oct 4.

PMID:
30287596
14.

Functional Decline and Resilience in Older Women Receiving Adjuvant Chemotherapy for Breast Cancer.

Hurria A, Soto-Perez-de-Celis E, Allred JB, Cohen HJ, Arsenyan A, Ballman K, Le-Rademacher J, Jatoi A, Filo J, Mandelblatt J, Lafky JM, Kimmick G, Klepin HD, Freedman RA, Burstein H, Gralow J, Wolff AC, Magrinat G, Barginear M, Muss H.

J Am Geriatr Soc. 2019 May;67(5):920-927. doi: 10.1111/jgs.15493. Epub 2018 Aug 26.

PMID:
30146695
15.

Impact of Genomic Assay Testing and Clinical Factors on Chemotherapy Use After Implementation of Standardized Testing Criteria.

Natsuhara KH, Losk K, King TA, Lin NU, Camuso K, Golshan M, Pochebit S, Brock JE, Bunnell CA, Freedman RA.

Oncologist. 2019 May;24(5):595-602. doi: 10.1634/theoncologist.2018-0154. Epub 2018 Aug 3.

PMID:
30076279
16.

Salvage of Threatened Cardiovascular Implantable Electronic Devices: Case Series and Review of Literature.

Simpson AM, Rockwell WT, Freedman RA, Rockwell WB.

Ann Plast Surg. 2018 Sep;81(3):340-343. doi: 10.1097/SAP.0000000000001474.

PMID:
29781854
17.

Adherence to Guidelines for Breast Surveillance in Breast Cancer Survivors.

Ruddy KJ, Sangaralingham L, Freedman RA, Mougalian SS, Neuman H, Greenberg C, Jemal A, Duma N, Haddad TC, Lemaine V, Ghosh K, Hieken TJ, Hunt K, Vachon C, Gross CP, Shah ND.

J Natl Compr Canc Netw. 2018 May;16(5):526-534. doi: 10.6004/jnccn.2018.7001.

PMID:
29752327
18.

Promoting Accrual of Older Patients with Cancer to Clinical Trials: An Alliance for Clinical Trials in Oncology Member Survey (A171602).

Freedman RA, Dockter TJ, Lafky JM, Hurria A, Muss HJ, Cohen HJ, Jatoi A, Kemeny MM, Ruddy KJ.

Oncologist. 2018 Sep;23(9):1016-1023. doi: 10.1634/theoncologist.2018-0033. Epub 2018 Apr 19.

19.

Breast cancer-specific survival by age: Worse outcomes for the oldest patients.

Freedman RA, Keating NL, Lin NU, Winer EP, Vaz-Luis I, Lii J, Exman P, Barry WT.

Cancer. 2018 May 15;124(10):2184-2191. doi: 10.1002/cncr.31308. Epub 2018 Mar 2.

20.

Morbidity of local therapy for locally advanced metastatic breast cancer: an analysis of the Surveillance, Epidemiology, and End Results (SEER)-Medicare Registry.

Fairweather M, Jiang W, Keating NL, Freedman RA, King TA, Nakhlis F.

Breast Cancer Res Treat. 2018 Jun;169(2):287-293. doi: 10.1007/s10549-018-4689-y. Epub 2018 Jan 27.

PMID:
29374851
21.

Variation in guideline-concordant care for elderly patients with metastatic breast cancer in the United States.

Poorvu PD, Vaz-Luis I, Freedman RA, Lin NU, Barry WT, Winer EP, Hassett MJ.

Breast Cancer Res Treat. 2018 Apr;168(3):727-737. doi: 10.1007/s10549-018-4659-4. Epub 2018 Jan 13.

PMID:
29332137
22.

Understanding Breast Cancer Knowledge and Barriers to Treatment Adherence: A Qualitative Study Among Breast Cancer Survivors.

Freedman RA, Revette AC, Hershman DL, Silva K, Sporn NJ, Gagne JJ, Kouri EM, Keating NL.

Biores Open Access. 2017 Dec 1;6(1):159-168. doi: 10.1089/biores.2017.0028. eCollection 2017.

23.

Treatment Patterns Among Women Diagnosed With Stage I-III Triple-negative Breast Cancer.

Sineshaw HM, Freedman RA, DeSantis CE, Jemal A.

Am J Clin Oncol. 2018 Oct;41(10):997-1007. doi: 10.1097/COC.0000000000000418.

PMID:
29278527
24.

Efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/HER2- advanced breast cancer: a review.

Freedman RA, Tolaney SM.

Breast Cancer Res Treat. 2018 Feb;167(3):607-614. doi: 10.1007/s10549-017-4560-6. Epub 2017 Nov 4. Review.

PMID:
29103175
25.

Breast Cancer Survivorship Care Variations Between Adjuvant Chemotherapy Regimens.

Leal AD, Van Houten H, Sangaralingham L, Freedman RA, Jemal A, Neuman HB, Haddad TC, Mutter RW, Keegan THM, Mougalian SS, Loprinzi CL, Gross CP, Shah N, Ruddy KJ.

Clin Breast Cancer. 2018 Aug;18(4):e513-e520. doi: 10.1016/j.clbc.2017.09.011. Epub 2017 Sep 22.

26.

Factors That Contributed to Black-White Disparities in Survival Among Nonelderly Women With Breast Cancer Between 2004 and 2013.

Jemal A, Robbins AS, Lin CC, Flanders WD, DeSantis CE, Ward EM, Freedman RA.

J Clin Oncol. 2018 Jan 1;36(1):14-24. doi: 10.1200/JCO.2017.73.7932. Epub 2017 Oct 16.

PMID:
29035645
27.

Patterns of axillary evaluation in older patients with breast cancer and associations with adjuvant therapy receipt.

Dominici LS, Sineshaw HM, Jemal A, Lin CC, King TA, Freedman RA.

Breast Cancer Res Treat. 2018 Jan;167(2):555-566. doi: 10.1007/s10549-017-4528-6. Epub 2017 Oct 9.

PMID:
28990127
28.

Implementation of Surgeon-Initiated Gene Expression Profile Testing (Onco type DX) Among Patients With Early-Stage Breast Cancer to Reduce Delays in Chemotherapy Initiation.

Losk K, Freedman RA, Lin NU, Golshan M, Pochebit SM, Lester SC, Natsuhara K, Camuso K, King TA, Bunnell CA.

J Oncol Pract. 2017 Sep;13(9):e815-e820. doi: 10.1200/JOP.2017.023788. Epub 2017 Aug 31. Erratum in: J Oncol Pract. 2017 Nov;13(11):776.

PMID:
28858535
29.

Trends in adjuvant therapies after breast-conserving surgery for hormone receptor-positive ductal carcinoma in situ: findings from the National Cancer Database, 2004-2013.

Sagara Y, Freedman RA, Wong SM, Aydogan F, Nguyen A, Barry WT, Golshan M.

Breast Cancer Res Treat. 2017 Nov;166(2):583-592. doi: 10.1007/s10549-017-4436-9. Epub 2017 Aug 3.

PMID:
28776282
30.

Use of Surveillance Mammography Among Older Breast Cancer Survivors by Life Expectancy.

Freedman RA, Keating NL, Pace LE, Lii J, McCarthy EP, Schonberg MA.

J Clin Oncol. 2017 Sep 20;35(27):3123-3130. doi: 10.1200/JCO.2016.72.1209. Epub 2017 Jul 27.

31.

Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer.

Ma CX, Bose R, Gao F, Freedman RA, Telli ML, Kimmick G, Winer E, Naughton M, Goetz MP, Russell C, Tripathy D, Cobleigh M, Forero A, Pluard TJ, Anders C, Niravath PA, Thomas S, Anderson J, Bumb C, Banks KC, Lanman RB, Bryce R, Lalani AS, Pfeifer J, Hayes DF, Pegram M, Blackwell K, Bedard PL, Al-Kateb H, Ellis MJC.

Clin Cancer Res. 2017 Oct 1;23(19):5687-5695. doi: 10.1158/1078-0432.CCR-17-0900. Epub 2017 Jul 5.

32.

Emerging Data and Current Challenges for Young, Old, Obese, or Male Patients with Breast Cancer.

Freedman RA, Partridge AH.

Clin Cancer Res. 2017 Jun 1;23(11):2647-2654. doi: 10.1158/1078-0432.CCR-16-2552.

33.

Impact of treatment regimen on acute care use during and after adjuvant chemotherapy for early-stage breast cancer.

Ruddy KJ, Van Houten HK, Sangaralingham LR, Freedman RA, Thompson CA, Hashmi SK, Jemal A, Haddad TC, Mougalian S, Herrin J, Gross C, Shah N.

Breast Cancer Res Treat. 2017 Aug;164(3):515-525. doi: 10.1007/s10549-017-4280-y. Epub 2017 May 10. Review.

PMID:
28493045
34.

State Variation in the Receipt of a Contralateral Prophylactic Mastectomy Among Women Who Received a Diagnosis of Invasive Unilateral Early-Stage Breast Cancer in the United States, 2004-2012.

Nash R, Goodman M, Lin CC, Freedman RA, Dominici LS, Ward K, Jemal A.

JAMA Surg. 2017 Jul 1;152(7):648-657. doi: 10.1001/jamasurg.2017.0115.

35.

Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503).

Kimmick GG, Major B, Clapp J, Sloan J, Pitcher B, Ballman K, Barginear M, Freedman RA, Artz A, Klepin HD, Lafky JM, Hopkins J, Winer E, Hudis C, Muss H, Cohen H, Jatoi A, Hurria A, Mandelblatt J.

Breast Cancer Res Treat. 2017 Jun;163(2):391-398. doi: 10.1007/s10549-017-4188-6. Epub 2017 Mar 10.

36.

Patterns of Utilization of Imaging Studies and Serum Tumor Markers Among Patients With De Novo Metastatic Breast Cancer.

Di Meglio A, Lin NU, Freedman RA, Barry WT, Winer EP, Vaz-Luis I.

J Natl Compr Canc Netw. 2017 Mar;15(3):316-324.

PMID:
28275032
37.

Prior Authorization for Medications in a Breast Oncology Practice: Navigation of a Complex Process.

Agarwal A, Freedman RA, Goicuria F, Rhinehart C, Murphy K, Kelly E, Mullaney E, St Amand M, Nguyen P, Lin NU.

J Oncol Pract. 2017 Apr;13(4):e273-e282. doi: 10.1200/JOP.2016.017756. Epub 2017 Feb 28.

PMID:
28245148
38.

Factors Associated with Early Mortality Among Patients with De Novo Metastatic Breast Cancer: A Population-Based Study.

Vaz-Luis I, Lin NU, Keating NL, Barry WT, Winer EP, Freedman RA.

Oncologist. 2017 Apr;22(4):386-393. doi: 10.1634/theoncologist.2016-0369. Epub 2017 Feb 27.

39.

Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials.

Basch E, Dueck AC, Rogak LJ, Minasian LM, Kelly WK, O'Mara AM, Denicoff AM, Seisler D, Atherton PJ, Paskett E, Carey L, Dickler M, Heist RS, Himelstein A, Rugo HS, Sikov WM, Socinski MA, Venook AP, Weckstein DJ, Lake DE, Biggs DD, Freedman RA, Kuzma C, Kirshner JJ, Schrag D.

JAMA Oncol. 2017 Aug 1;3(8):1043-1050. doi: 10.1001/jamaoncol.2016.6749.

40.

Growing Use of Contralateral Prophylactic Mastectomy Despite no Improvement in Long-term Survival for Invasive Breast Cancer.

Wong SM, Freedman RA, Sagara Y, Aydogan F, Barry WT, Golshan M.

Ann Surg. 2017 Mar;265(3):581-589. doi: 10.1097/SLA.0000000000001698.

PMID:
28169929
41.

Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527.

Freedman RA, Foster JC, Seisler DK, Lafky JM, Muss HB, Cohen HJ, Mandelblatt J, Winer EP, Hudis CA, Partridge AH, Carey LA, Cirrincione C, Moreno-Aspitia A, Kimmick G, Jatoi A, Hurria A.

J Clin Oncol. 2017 Feb;35(4):421-431. doi: 10.1200/JCO.2016.69.4182. Epub 2016 Dec 19.

42.

Effect of the LIVESTRONG at the YMCA exercise program on physical activity, fitness, quality of life, and fatigue in cancer survivors.

Irwin ML, Cartmel B, Harrigan M, Li F, Sanft T, Shockro L, O'Connor K, Campbell N, Tolaney SM, Mayer EL, Yung R, Freedman RA, Partridge AH, Ligibel JA.

Cancer. 2017 Apr 1;123(7):1249-1258. doi: 10.1002/cncr.30456. Epub 2016 Nov 28.

43.

Surveillance Mammography in Older Patients With Breast Cancer-Can We Ever Stop?: A Review.

Freedman RA, Keating NL, Partridge AH, Muss HB, Hurria A, Winer EP.

JAMA Oncol. 2017 Mar 1;3(3):402-409. doi: 10.1001/jamaoncol.2016.3931. Review.

44.

Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511).

Freedman RA, Seisler DK, Foster JC, Sloan JA, Lafky JM, Kimmick GG, Hurria A, Cohen HJ, Winer EP, Hudis CA, Partridge AH, Carey LA, Jatoi A, Klepin HD, Citron M, Berry DA, Shulman LN, Buzdar AU, Suman VJ, Muss HB.

Breast Cancer Res Treat. 2017 Jan;161(2):363-373. doi: 10.1007/s10549-016-4051-1. Epub 2016 Nov 19.

45.

Heart Transplantation on a Desert Island? Self-Sacrifice and Slippery Slopes.

Battin MP, Edwards JH, Freedman RA.

Ann Thorac Surg. 2016 Dec;102(6):1783-1784. doi: 10.1016/j.athoracsur.2016.09.088. No abstract available.

PMID:
27847034
46.

Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab.

Vaz-Luis I, Lin NU, Keating NL, Barry WT, Lii J, Burstein HJ, Winer EP, Freedman RA.

Breast Cancer Res Treat. 2016 Aug;159(1):151-62. doi: 10.1007/s10549-016-3927-4. Epub 2016 Aug 2.

PMID:
27484879
47.

Reply to K. Lin et al.

Sagara Y, Freedman RA, Mallory MA, Wong SM, Barry WT, Golshan M.

J Clin Oncol. 2016 Oct 1;34(28):3485-6. doi: 10.1200/JCO.2016.68.7723. Epub 2016 Jul 25. No abstract available.

PMID:
27458285
48.

Learning from social media: utilizing advanced data extraction techniques to understand barriers to breast cancer treatment.

Freedman RA, Viswanath K, Vaz-Luis I, Keating NL.

Breast Cancer Res Treat. 2016 Jul;158(2):395-405. doi: 10.1007/s10549-016-3872-2. Epub 2016 Jun 23.

49.

Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis.

Di Meglio A, Freedman RA, Lin NU, Barry WT, Metzger-Filho O, Keating NL, King TA, Sertoli MR, Boccardo F, Winer EP, Vaz-Luis I.

Breast Cancer Res Treat. 2016 Jun;157(3):587-96. doi: 10.1007/s10549-016-3845-5. Epub 2016 Jun 6.

PMID:
27271765
50.

Association of Breast Cancer Knowledge With Receipt of Guideline-Recommended Breast Cancer Treatment.

Freedman RA, Kouri EM, West DW, Lii J, Keating NL.

J Oncol Pract. 2016 Jun;12(6):e613-25. doi: 10.1200/JOP.2015.008508. Epub 2016 May 10.

Supplemental Content

Loading ...
Support Center